Onyx Shares Down Nearly 30%

Shares of Onyx Pharmaceuticals fell nearly 30% on Monday after data showed that its kidney cancer drug Nexavar did not work in patients with advanced skin cancer.

Onxy and its partner Bayer of Germany said a late-stage trial of the drug in combination with chemotherapy did not meet its main goal of improving progression-free survival, or the period in which a patient experiences no meaningful tumor growth.

"We are disappointed, first and foremost for the patients with refractory metastatic melanoma for whom treatment options are so limited," said Hollings Renton, the chief executive of Onyx, in a statement.

Renton said the companies will continue to test the drug in other cancers. A late stage trial of Nexavar is currently under way in liver cancer and a late-stage, or Phase III, trial of the drug in lung cancer was initiated earlier this year.

Nexavar, also known as sorafenib, is a tablet that blocks several kinases, or enzymes, that are involved in cell proliferation or in supplying blood to tumors, a process known as angiogenesis.

Last month Bayer said it expected sales of Nexavar to reach about $133 million this year and eventually to generate sales of at least $1 billion. The drug competes with Pfizer's Sutent.

Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More*

Don't Miss

U.S. Video

  • CNBC's Tyler Mathisen looks back at the week's top business and financial stories. The markets were closed for Thanksgiving, but did manage to hit new highs. Low oil prices gave consumers more money to spend for Black Friday.

  • Cyber Monday deals on Walmart's website on Dec. 2, 2013.

    CNBC's Tyler Mathisen looks ahead to what are likely to be next week's top stories. The jobs report comes out this week, as do auto sales. And the Rockefeller Center Christmas tree is lit.

  • Following last week's wild energy ride, analysts expect oil prices to continue to drop during the holiday season. CNBC's Patti Domm reports.